Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

Carlos A Narvaez; Steven E Schild; Stefan Janssen; Ursula Schroeder; Karl L Bruchhage; Samer G Hakim; Dirk Rades

doi:10.21873/anticanres.14798

Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

Carlos A Narvaez, Steven E Schild, Stefan Janssen, Ursula Schroeder, Karl L Bruchhage, Samer G Hakim, Dirk Rades

Abstract

BACKGROUND/AIM: Patients with unresectable head-and-neck cancer (SCCHN) unable to tolerate radiochemotherapy may receive unconventionally fractionated radiotherapy. This retrospective study compared both treatments.

PATIENTS AND METHODS: Eight patients unsuitable for chemotherapy were assigned to accelerated fractionation with concomitant boost (AF-CB, 69.6 Gy/39 fractions) over 5.5 weeks (group A) and 72 patients to cisplatin-based radiochemotherapy (70 Gy/35 fractions) over 7 weeks (group B). Groups were matched (cancer site, gender, age, performance score, T-/N-stage, histologic grade) and compared for loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and toxicities.

RESULTS: LRC, MFS, OS and radiation-related toxicities were not significantly different between groups A and B. Improved outcomes were associated with favorable cancer site, better performance score and T3-stage. In group B, toxicity led to reduction/discontinuation of chemotherapy in 38.9% and interruptions of radiotherapy >7 days in 19.3% of patients.

CONCLUSION: AF-CB appeared a reasonable alternative for patients who cannot safely receive radio-chemotherapy for unresectable SCCHN.

Original language	English
Journal	Anticancer Research
Volume	41
Issue number	1
Pages (from-to)	477-484
Number of pages	8
ISSN	0250-7005
DOIs	https://doi.org/10.21873/anticanres.14798
Publication status	Published - 01.01.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.14798

Cite this

Narvaez, C. A., Schild, S. E., Janssen, S., Schroeder, U., Bruchhage, K. L., Hakim, S. G., & Rades, D. (2021). Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). Anticancer Research, 41(1), 477-484. https://doi.org/10.21873/anticanres.14798

@article{6a462e4ca95c443dad1965588407f0a1,

title = "Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)",

abstract = "BACKGROUND/AIM: Patients with unresectable head-and-neck cancer (SCCHN) unable to tolerate radiochemotherapy may receive unconventionally fractionated radiotherapy. This retrospective study compared both treatments.PATIENTS AND METHODS: Eight patients unsuitable for chemotherapy were assigned to accelerated fractionation with concomitant boost (AF-CB, 69.6 Gy/39 fractions) over 5.5 weeks (group A) and 72 patients to cisplatin-based radiochemotherapy (70 Gy/35 fractions) over 7 weeks (group B). Groups were matched (cancer site, gender, age, performance score, T-/N-stage, histologic grade) and compared for loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and toxicities.RESULTS: LRC, MFS, OS and radiation-related toxicities were not significantly different between groups A and B. Improved outcomes were associated with favorable cancer site, better performance score and T3-stage. In group B, toxicity led to reduction/discontinuation of chemotherapy in 38.9% and interruptions of radiotherapy >7 days in 19.3% of patients.CONCLUSION: AF-CB appeared a reasonable alternative for patients who cannot safely receive radio-chemotherapy for unresectable SCCHN.",

author = "Narvaez, {Carlos A} and Schild, {Steven E} and Stefan Janssen and Ursula Schroeder and Bruchhage, {Karl L} and Hakim, {Samer G} and Dirk Rades",

year = "2021",

month = jan,

day = "1",

doi = "10.21873/anticanres.14798",

language = "English",

volume = "41",

pages = "477--484",

journal = "Anticancer Research",

issn = "0250-7005",

number = "1",

}

Narvaez, CA, Schild, SE, Janssen, S , Schroeder, U , Bruchhage, KL, Hakim, SG & Rades, D 2021, 'Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)', Anticancer Research, vol. 41, no. 1, pp. 477-484. https://doi.org/10.21873/anticanres.14798

Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). / Narvaez, Carlos A; Schild, Steven E; Janssen, Stefan et al.

In: Anticancer Research, Vol. 41, No. 1, 01.01.2021, p. 477-484.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

AU - Narvaez, Carlos A

AU - Schild, Steven E

AU - Janssen, Stefan

AU - Schroeder, Ursula

AU - Bruchhage, Karl L

AU - Hakim, Samer G

AU - Rades, Dirk

PY - 2021/1/1

Y1 - 2021/1/1

N2 - BACKGROUND/AIM: Patients with unresectable head-and-neck cancer (SCCHN) unable to tolerate radiochemotherapy may receive unconventionally fractionated radiotherapy. This retrospective study compared both treatments.PATIENTS AND METHODS: Eight patients unsuitable for chemotherapy were assigned to accelerated fractionation with concomitant boost (AF-CB, 69.6 Gy/39 fractions) over 5.5 weeks (group A) and 72 patients to cisplatin-based radiochemotherapy (70 Gy/35 fractions) over 7 weeks (group B). Groups were matched (cancer site, gender, age, performance score, T-/N-stage, histologic grade) and compared for loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and toxicities.RESULTS: LRC, MFS, OS and radiation-related toxicities were not significantly different between groups A and B. Improved outcomes were associated with favorable cancer site, better performance score and T3-stage. In group B, toxicity led to reduction/discontinuation of chemotherapy in 38.9% and interruptions of radiotherapy >7 days in 19.3% of patients.CONCLUSION: AF-CB appeared a reasonable alternative for patients who cannot safely receive radio-chemotherapy for unresectable SCCHN.

AB - BACKGROUND/AIM: Patients with unresectable head-and-neck cancer (SCCHN) unable to tolerate radiochemotherapy may receive unconventionally fractionated radiotherapy. This retrospective study compared both treatments.PATIENTS AND METHODS: Eight patients unsuitable for chemotherapy were assigned to accelerated fractionation with concomitant boost (AF-CB, 69.6 Gy/39 fractions) over 5.5 weeks (group A) and 72 patients to cisplatin-based radiochemotherapy (70 Gy/35 fractions) over 7 weeks (group B). Groups were matched (cancer site, gender, age, performance score, T-/N-stage, histologic grade) and compared for loco-regional control (LRC), metastases-free survival (MFS), overall survival (OS) and toxicities.RESULTS: LRC, MFS, OS and radiation-related toxicities were not significantly different between groups A and B. Improved outcomes were associated with favorable cancer site, better performance score and T3-stage. In group B, toxicity led to reduction/discontinuation of chemotherapy in 38.9% and interruptions of radiotherapy >7 days in 19.3% of patients.CONCLUSION: AF-CB appeared a reasonable alternative for patients who cannot safely receive radio-chemotherapy for unresectable SCCHN.

UR - http://www.scopus.com/inward/record.url?scp=85099709063&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/dcdb4713-0614-30e5-8cec-ca14255ab6c3/

U2 - 10.21873/anticanres.14798

DO - 10.21873/anticanres.14798

M3 - Journal articles

C2 - 33419846

VL - 41

SP - 477

EP - 484

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -

Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this